Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
EC$17.29-0.11(-0.63%)Ecopetrol announces the dates for the presentation of its third quarter 2026 results report and conference call Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) (the "Company") announces that on Tuesday, November 10, 2026, it plans to release its financial and...[9:58:00 PM ET]KMB$108.00-1.63(-1.49%)Kimberly-Clark Corporation Announces Extension of the Expiration Date for Exchange Offers for Kenvue Notes Kimberly-Clark Corporation (NASDAQ: KMB) ("Kimberly-Clark") announced today the extension of the expiration date of the offers to exchange (each an...[9:29:00 PM ET]AOS$62.06+0.15(+0.24%)A. O. Smith Announces Majority Interest of China Business Acquired by CPE; A. O. Smith to Retain 19% Stake and Long-Term Brand License Global water technology company A. O. Smith Corporation ("A. O. Smith" or "the Company") (NYSE: AOS) today announced definitive agreements with CPE,...[8:55:00 PM ET]TOPS$0.31+0.03(+10.36%)TOP Ships Inc. Announces $5.0 Million Private Placement of Senior Convertible Notes and Warrants[8:54:57 PM ET]PAC$224.01-0.66(-0.29%)Grupo Aeroportuario del Pacífico Announces Dividend Payment Date as Approved at the Annual General Ordinary Shareholders’ Meeting[8:53:07 PM ET]TOPS$0.31+0.03(+10.36%)TOP Ships Inc. Announces Reverse Stock Split[8:43:02 PM ET]BTCWF$0.08-0.00(-5.00%)Bluesky Digital Announces Director Change[8:02:00 PM ET]CCL$27.72+0.86(+3.20%)Princess Cruises Sets the Stage for Extraordinary Discovery Down Under in 2028-29 Princess Cruises unveils its 2028–29 Australia and New Zealand season alongside the 2029 Grand World Odyssey. Together, this collection offers four...[8:00:00 PM ET]HTHIY$36.02+0.56(+1.58%)Hitachi Unveils a New Global Digital Services Company Turning Cloud, Data and AI Into Measurable Business Outcomes: Hitachi Digital[8:00:00 PM ET]BFH$102.61+0.89(+0.87%)Bread Financial Announces Pricing of an Offering of Depositary Shares Representing Interests in Its Series C Preferred Stock[7:52:45 PM ET]

AEON · AMEX

AEON Biopharma, Inc.

$0.25 0.00 (+0.04%)

Company overview

AEON Biopharma, Inc. is a biopharmaceutical company that focuses on developing botulinum toxins for the treatment of debilitating medical conditions. It also develops the 900 kDa botulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. Incorporated in 2012, it is headquartered in Newport Beach, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
AMEX
Market cap
$12.5M
Employees
5
Headquarters
Newport Beach, CA
Website
aeonbiopharma.com
CEO
Robert Bancroft
Listed
July 24, 2023
P/E
-0.05
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$19,000
Operating income
-$18.3M
EBITDA
-$18.2M
Net income
-$60.1M
EPS
-$5.03
Total assets
$8.6M
Total debt
$2.6M
Earnings yield
-2,012.00%

Price chart

0.140.380.620.861.11
AEON 1D AMEX O0.24H0.25L0.24C0.25+0.01 (+4.17%)Vol13.13K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
AEONAEON Biopharma, Inc. Stock news AEON STRATEGIES LTD. Provides Update on Anticipated Late Filing of Annual Financial Statements TheNewswire
AEONAEON Biopharma, Inc. Stock news Aeon Strategies Ltd. Announces Anticipated Late Filing of Annual Financial Statements and Application for Management Cease Trade Order TheNewswire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 GlobeNewswire
AEONAEON Biopharma, Inc. Stock news Apple To $355? Here Are 10 Top Analyst Forecasts For Thursday Benzinga
AEONAEON Biopharma, Inc. Press release AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Announces Positive Pilot Forced Degradation Results Supporting Analytical Comparability of ABP-450 to BOTOX® GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma to Participate in Lake Street Capital Markets' 10th Annual Best Ideas Growth (BIG10) Conference GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Reports Expanded Structural Data Supporting Molecular Similarity of ABP-450 to BOTOX® GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards GlobeNewsWire
AEONAEON Biopharma, Inc. Press release Bitget Launchpool adds AEON (AEON) with 1.1M in Token Rewards GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewsWire
AEONAEON Biopharma, Inc. Stock news AEON Biopharma Sets Annual Shareholder Meeting Globe News Wire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Sets Annual Shareholder Meeting GlobeNewsWire
AEONAEON Biopharma, Inc. Stock news Aerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Head to Head Survey Defense World
AEONAEON Biopharma, Inc. Press release AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711 GlobeNewsWire
AEONAEON Biopharma, Inc. Press release AEON Biopharma Receives Additional Notice Related to NYSE American Continued Listing Standards GlobeNewsWire
See more
FAQ

Questions about AEON Biopharma, Inc.

What does AEON Biopharma, Inc. do?
AEON Biopharma, Inc. is a biopharmaceutical company that focuses on developing botulinum toxins for the treatment of debilitating medical conditions. It also develops the 900 kDa botulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. Incorporated in 2012, it is headquartered in Newport Beach, California.
What is AEON's market cap?
AEON Biopharma, Inc. (AEON) is a listed stock with a live quote. The latest market cap on this page is $12.5M.
Where is AEON Biopharma, Inc. headquartered?
AEON Biopharma, Inc. is headquartered in Newport Beach, CA.
How do I get AEON news from the API?
Call GET /v1/news?tickers=AEON. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does AEON news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for AEON, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the AEON price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs